Evaxion to present new data on EVX-04, a therapeutic AML vaccine, at EHA 2026 Congress.

Evaxion will present preclinical data on EVX-04, an AI-designed off-the-shelf vaccine targeting acute myeloid leukemia (AML), at the EHA 2026 Congress in June. EVX-04 targets unique tumor antigens and has shown promise in preventing tumor growth in preclinical models. The company plans to submit a clinical trial application in the second half of 2026, advancing toward clinical testing. This development offers hope for improved AML treatment options, especially for patients unfit for intensive therapies.